For decades, the process of drug discovery has been a prolonged, costly, and unpredictable endeavor — an effort that ...

True ROI for R&D won't come from the tool that generates 10,000 new ideas. It will come from the tool that confidently tells ...

Bioprinting is rapidly moving from research labs into commercial reality, and it is reshaping how the pharmaceutical and ...

Explore how AI-driven multiomics is reshaping drug discovery and personalized medicine development through innovative data ...

The integration of bioinformatics, machine learning and multi-omics has transformed soil science, providing powerful tools to ...

BostonGene has entered a new collaboration with AstraZeneca to apply its foundation AI model to oncology drug development, aiming to improve early trial decision-making around safety, efficacy, and ...

TEL AVIV, Israel, Jan. 9, 2026 /PRNewswire/ -- CytoReason, a leader in AI-powered computational disease modeling, today announced the expansion of its collaboration with Sanofi for the third time.

MIT researchers are now turning the prolific Boltz series of models into a software company that promotes open science for AI-guided therapeutics.

The DMTA cycle depends on clear data flow, yet most labs still work across disconnected systems. Sean McGee, Director of ...

La Jolla scientists are stepping into a national push to get new medicines from lab bench to bedside faster. The project, ...

Learn about Agentic AI and its role in enhancing decision-making in drug discovery through planned actions and verified ...